Date: 2012-04-26
Type of information:
Product name: Huntexil®
Compound: pridopidine, previously designated ACR16
Therapeutic area:
Action mechanism: Pridopidine belongs to a new class of pharmaceutically active agents named dopidines, which are characterized by their unique psychomotor-function stabilizing properties.
Company: Neurosearch (Denmark)
Disease:
Huntington's disease
Latest news: * On April 2012, NeuroSearch has announced that the company is seeking a partner for the global marketing rights for Huntexil® in order to provide financing to conduct the Prime-HD study with Huntexil®, and the further development of the asset. The Prime-HD study will not be initiated before financing is secured to finalise the study.
Upon signing of a partnership for Huntexil® based on global rights, NeuroSearch will be open to discuss various development scenarios, business models and strategic alternatives. Concurrently, NeuroSearch is also seeking support among existing and potential new investors for their participation in a possible capital increase. This will enable NeuroSearch to retain all rights to Huntexil®. On 31 March 2012, the company\'s cash and cash equivalents including securities totalled DKK 144 million - € 19 million (DKK 412 million at 31 March 2011).
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
